XBiotech Inc. XBIT
1.99 USD +0.07 (+3.65%)
At closeNov 3, 2026, 4:00 PM EST
1.99 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
1.90 Day range 2.13
1.80 52-week range 3.44
- YTD
- -16.74%
- 1 year
- -13.10%
- Market cap
- 60.67M
- EPS (ttm)
- -1.48
- Shares out
- 30.48M
- Forward P/E
- 34.62
- YTD return
- -16.74%
- 1-year return
- -13.10%
- Volume
- 132.75K
- Avg volume
- 56.45K
- Open
- 1.90
- Previous close
- 1.92
- Day's range
- 1.90 – 2.13
- 52-week range
- 1.80 – 3.44
- Earnings date
- Nov 9, 2023
2Y -5.31 (-72.74%)
Key statistics
- Enterprise value
- 21.37M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -22.16M
- Total cash
- 183.12M
- Total debt
- 10.00M
- Return on equity
- -15.75%
- Short % of float
- 4.50%
- 50-day average
- 7.07
- 200-day average
- 7.11
Next earnings
Nov 9, 2023
Expected Nov 9, 2023. Consensus EPS estimate 0.00.
Financials — quick view
XBIT Revenue — quarterly 0
XBIT Net income — quarterly -6.73M
XBIT EPS — quarterly -0.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.16 | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -0.43 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.33 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 10, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 7, 2020 | Piper Sandler | main | — | Overweight |
| Dec 11, 2019 | Piper Sandler | main | — | Overweight |
| Jun 14, 2019 | Piper Sandler | init | — | Overweight |
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- xbiotech.com
News
XBiotech Appoints Jan-Paul Simard Co-CEO, Effective Oct. 23 
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers 
XBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing Threshold Of 42, More Surviving Patients 
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer 
XBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average – What’s Next? - XBiotech Says IND Application For V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path For U.S. Patient Enrollment
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis 
XBiotech Q1 EPS $(0.18) Up From $(0.36) YoY 
Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB) 
Head-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM)
Your note
Sign in to keep a note on XBIT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 4.10% | 1,250,001 | 5.63M | Sep 29, 2024 |
| Vanguard Group Inc | 3.48% | 1,061,979 | 4.78M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.48% | 452,264 | 2.04M | Sep 29, 2024 |
| Millennium Management Llc | 0.92% | 281,019 | 1.26M | Sep 29, 2024 |
| UBS Asset Management Americas Inc | 0.83% | 253,770 | 1.14M | Sep 29, 2024 |
| State Street Corporation | 0.74% | 224,595 | 1.01M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.04% | 623,356 | 2.81M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.48% | 450,934 | 2.03M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.96% | 292,547 | 1.32M | Sep 29, 2024 |
| iShares Russell 2000 Value ETF | 0.62% | 187,801 | 845.10K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.61% | 186,990 | 841.46K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 111,517 | 501.83K | Oct 30, 2024 |